Journal article
The Economic Impact of Treatment Sequencing in Chronic Lymphocytic Leukemia in Canada Using Venetoclax plus Obinutuzumab
Abstract
BACKGROUND: Bruton tyrosine kinase inhibitors (BTKis) represent an advancement in chronic lymphocytic leukemia; however, these agents are administered continuously until disease progression or unacceptable toxicity, raising concerns about their affordability. Venetoclax in combination with obinutuzumab (VO) is a fixed-duration (12-month) treatment, approved in Canada in 2020. This study estimated the total cumulative cost of different treatment …
Authors
Guinan K; Mathurin K; Lachaine J; Roc NP; Bull S-J; Tankala D; Barakat S; Manzoor BS; Hillis C; Banerji V
Journal
Cancers, Vol. 16, No. 18,
Publisher
MDPI
DOI
10.3390/cancers16183182
ISSN
2072-6694